Related Experiment Video
Updated: Feb 21, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
24.8K
Cognitive Dysfunction and Single Nucleotide Polymorphisms in Hepatitis C Virus-Infected Persons: A Systematic Review
Tatiana Lins Carvalho1, Raul Emídio Lima2, Gustavo Henrique Belarmino Góes3
11 Hospital Universitário Oswaldo Cruz, Universidade de Pernambuco (UPE) , Recife, PE, Brazil .
Viral Immunology
|October 11, 2017
Summary
This review found the APOE-ɛ4 allele was less frequent in hepatitis C virus (HCV) patients with memory and attention issues. More research is needed due to limited data and conflicting findings on HCV, cognitive function, and genetic variations.
Area of Science:
- Neuroscience
- Genetics
- Hepatology
Background:
- Hepatitis C virus (HCV) infection is linked to cognitive dysfunction.
- Single nucleotide polymorphisms (SNPs) may influence cognitive alterations in HCV patients.
Purpose of the Study:
- To systematically review literature on cognitive dysfunction and SNPs in people with HCV.
- To identify associations between genetic factors and cognitive impairments in HCV.
Main Methods:
- Systematic literature search across six databases (SciELO, MEDLINE, PubMed, HighWire, LILACS, ScienceDirect).
- Two-stage study selection process involving initial search and full-text review.
- Inclusion of one study meeting eligibility criteria for final analysis.
Main Results:
- The APOE-ɛ4 allele frequency was significantly lower in HCV patients with mild liver disease who had impaired working memory (p=0.003) and attention (p=0.008).
- This finding contrasts with other studies associating higher APOE-ɛ4 frequency with cognitive decline.
Conclusions:
- Limited literature exists on HCV, cognitive alterations, and SNPs.
- Further large-scale studies are required to clarify the relationship between HCV, cognitive changes, and genetic variations due to divergent findings.
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
295
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
295
01:05Single Nucleotide Polymorphisms-SNPs
18.7K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
18.7K
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
223
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
223
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
20
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
20
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
270
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
270
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
22
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
22